Candida albicans intralesional injection immunotherapy of warts.
Often, the treatment of verrucae is frustrating for both the physician and patient. Treatment may be painful, scarring, ineffective, and costly. The object of this study was to compare the clinical outcomes and safety of Candida albicans intralesional injection immunotherapy (CI) versus conventional wart treatment. The results of a prospective, nonrandomized, open-label, comparison study are presented. CI is a novel, simple, and inexpensive modality for the treatment of verruca vulgaris (VV), including the plantar wart (PW) type. CI appears safe and well tolerated and is well suited for multiple warts on hands and fingers, PWs, and recalcitrant warts. Uninjected warts also may regress during CI. The new phenomenon of postimmunotherapy-revealed cicatrix (PIRC) is described. CI represents an off-label usage of Candida extract.
D000293:Adolescent; D000328:Adult; D000946:Antigens, Fungal / Q000008:administration & dosage*; D002176:Candida albicans / Q000276:immunology*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012871:Skin Diseases / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome; D014860:Warts / Q000175:diagnosis / Q000628:therapy*
D000946:Antigens, Fungal